Article
Development of N-terminally modified variants of the CXCR4-antagonizing peptide EPI-X4 with increased plasma stability
2022-11-01
Abstract excerpt
EPI-X4 is a natural peptide antagonist of CXCR4, an established drug target in inflammatory diseases and cancer. Advanced derivatives of EPI-X4, such as EPI-X4 JM#21, have shown promising therapeutic effects in animal models of CXCR4-associated diseases but suffer from poor stability in blood. We here aimed to design and characterize EPI-X4 analogs that effectively antagonize CXCR4 while remaining stable in human...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 95aeba7f-12d9-5584-a80f-ae5f5e7df977
- DOI
- 10.22541/au.166733107.78559129/v1
